Puberty blockers are not safe and not reversible
Riley Gaines said:
“No, it's not. That's a lie. That is a lie.”
Concerns about long-term effects of puberty blockers on bone density and brain development have appeared in mainstream media and some regulatory reviews, so a flat denial of safety and reversibility can sound like it reflects emerging scientific caution.
The clinical consensus, set out in guidance from the Endocrine Society and WPATH, is that GnRH analogues are reversible in their primary effects on pubertal development: when the medication stops, puberty resumes. There are genuine open questions about bone density and long-term outcomes that researchers are actively monitoring, and those questions deserve serious attention rather than dismissal. But open questions are not the same as evidence of irreversibility, and the distance between 'we are still learning' and 'that is a lie' is very large. Young people and families trying to make careful, informed decisions about care need accurate information about what the evidence does and does not show, and overstating danger in either direction takes that from them.
Young people and parents seeking accurate information to make informed decisions about care: overstating danger pushes them away from treatment that has a substantial evidence base for reducing gender dysphoria.